# OnCo record oligodendroglioma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/oligodendroglioma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "oligodendroglioma" ;
  schema:name "Oligodendroglioma, IDH-mutant and 1p/19q-codeleted"@en ;
  schema:alternateName "Oligodendroglioma"@en, "Anaplastic oligodendroglioma"@en, "1p/19q codeleted glioma"@en ;
  schema:description "Oligodendroglioma is the adult brain tumour most responsive to chemotherapy. It is recognised by an IDH mutation together with loss of parts of chromosomes 1 and 19, and after surgery it is treated with radiotherapy plus the PCV drug combination, or, for small grade 2 tumours, with vorasidenib or watchful waiting."@en ;
  schema:url <https://onco.cc/cancers/oligodendroglioma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Oligodendroglioma> ;
  schema:citation <https://en.wikipedia.org/wiki/Oligodendroglioma>, <https://doi.org/10.1200/JCO.2012.43.2674>, <https://doi.org/10.1200/JCO.2012.43.2229> ;
  onco:tag "subtype-page", "cns" ;
  onco:related <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/idh-mutant-astrocytoma/>, <https://onco.cc/cancers/brain-tumours/> ;
  onco:technologies <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/extent-of-resection/> ;
  onco:targets <https://onco.cc/targets/idh/> ;
  onco:drugs <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:pathways <https://onco.cc/pathways/glioma-signalling/> ;
  onco:terms <https://onco.cc/terms/re-irradiation/> ;
  onco:trials <https://onco.cc/trials/rtog-9402/>, <https://onco.cc/trials/eortc-26951/>, <https://onco.cc/trials/indigo/> ;
  onco:pipeline <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/safusidenib/>, <https://onco.cc/technologies/methylation-profiling/> ;
  onco:standardOfCare <https://onco.cc/terms/extent-of-resection/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/trials/indigo/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/trials/rtog-9402/>, <https://onco.cc/trials/eortc-26951/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/terms/re-irradiation/>, <https://onco.cc/drugs/bevacizumab-glioma/> .